[Corrigendum] Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer
- Authors:
- Published online on: February 23, 2021 https://doi.org/10.3892/ol.2021.12572
- Article Number: 311
-
Copyright : © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article
Oncol Lett 17: [Related article:] 5469-5480, 2019; DOI: 10.3892/ol.2019.10277
Following the publication of the above paper, which was entitled ‘Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer’, it was drawn to the Editor's attention that the use of “Recurrence Score”, as featured in the title and in the main text of the paper, was an infringement of registered trademarks held by Genomic Health, Inc. with its Oncotype DX test. It should also be noted that Genomic Health, Inc. were involved neither in the preparation of the article nor in the underlying testing with its Oncotype DX test.
A suggestion was made that the term ‘recurrence score’ could have been written as ‘relapse score’ without losing the intended meaning and without infringing upon the trademark. Therefore, the titled has been rephrased to ‘Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer’, as shown above; furthermore, ‘recurrence score’ should have been written as ‘relapse score’ at the start of the abstract on p. 5469, in the second sentence of the second paragraph of the Introduction (p. 5469), and in the titles and/or legends of Tables I–VII and Figs. 1–4.
